A phase II study of neoadjuvant FOLFIRINOX in patients with borderline or locally advanced unresectable pancreatic ductal adenocarcinoma. - NAT FFX for BR or UR-LA PDAC

Toyama Hirochika0 个研究点目标入组 25 人开始时间: 2020年1月28日最近更新: 2023年10月17日

试验速览

暂无简介。

•Histologically diagnosed pancreatic ducatal adenocarcinoma: including suspected case of adenocarcinoma by a cytology.
•- Anable to undergo dynamic computed tomography.
•- Radiologically diagnosed borderline resectable or locally advanced unresectable pancreatic ductal adenocarcinoma according to NCCN guideline 2018.
•- Age 20 - 75
•- ECOG performance status 0 or 1
•- No treatment history for pancreatic ductal adenocarcinoma.
•- No more than grade 1 peripheral sensory and motor neuropathy.
•- Good functional capacities of main organs within two weekes before enrollment.
•- Expected survival time more than 3 months.
•- Feasible for pancreatic resection.
•- With imformed written consent.

•- Homozygous or double heterozygous fot UGT1A1*28, 6.
•- Bleeding disorders
•- Administration of steroid or immunosuppressive drug
•- Severe complication of main organs
•- Interstitial pneumonia, pulmonary fibrosis, or severe emphysema
•- Uncontrollable infectious disease
•- Uncontrollable diarrhea
•- Pregnancy
•- Double cancer with disease-free survival less than 5 years: excluding cured cutaneous basal cell cancer and gastrointestinal cancer with endoscopically curative resection.
•- Investigator judgement that the patient should not participate for any reason

发起方

Toyama Hirochika